Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Luteolin Arrests Cell Cycling, Induces Apoptosis and Inhibits the JAK/STAT3 Pathway in Human Cholangiocarcinoma Cells

  • Published : 2014.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Cholangiocarcinoma (CCA) is one of the aggressive cancers with a very poor prognosis. Several efforts have been made to identify and develop new agents for prevention and treatment of this deadly disease. In the present study, we examined the anticancer effect of luteolin on human CCA, KKU-M156 cells. Sulforhodamine B assays showed that luteolin had potent cytotoxicity on CCA cells with IC50 values of $10.5{\pm}5.0$ and $8.7{\pm}3.5{\mu}M$ at 24 and 48 h, respectively. Treatment with luteolin also caused a concentration-dependent decline in colony forming ability. Consistent with growth inhibitory effects, luteolin arrested cell cycle progression at the G2/M phase in a dose-dependent manner as assessed by flow cytometry analysis. Protein expression of cyclin A and Cdc25A was down-regulated after luteolin treatment, supporting the arrest of cells at the G2/M boundary. Besides evident G2/M arrest, luteolin induced apoptosis of KKU-M156 cells, demonstrated by a distinct sub-G1 apoptotic peak and fluorescent dye staining. A decrease in the level of anti-apoptotic Bcl-2 protein was implicated in luteolin-induced apoptosis. We further investigated the effect of luteolin on JAK/STAT3, which is an important pathway involved in the development of CCA. The results showed that interleukin-6 (IL-6)-induced JAK/STAT3 activation in KKU-M156 cells was suppressed by treatment with luteolin. Treatment with a specific JAK inhibitor, AG490, and luteolin diminished IL-6-stimulated CCA cell migration as assessed by wound healing assay. These data revealed anticancer activity of luteolin against CCA so the agent might have potential for CCA prevention and therapy.

Keywords

References

  1. Ali R, Mirza Z, Ashraf GM, et al (2012). New anticancer agents: recent developments in tumor therapy. Anticancer Res, 32, 2999-3005.
  2. Butthongkomvong K, Sirachainan E, Jhankumpha S, Kumdang S, Sukhontharot OU (2013). Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. Asian Pac J Cancer Prev, 14, 3565-8. https://doi.org/10.7314/APJCP.2013.14.6.3565
  3. Czabotar PE, Lessene G, Strasser A, Adams JM (2014). Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol, 15, 49-63. https://doi.org/10.1038/nrm3722
  4. Dokduang H, Juntana S, Techasen A, et al (2013). Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. Tumour Biol, 34, 3519-28. https://doi.org/10.1007/s13277-013-0930-9
  5. George VC, Naveen Kumar DR, Suresh PK, Kumar S, Kumar RA (2013). Comparative studies to evaluate relative in vitro potency of luteolin in inducing cell cycle arrest and apoptosis in HaCaT and A375 cells. Asian Pac J Cancer Prev, 14, 631-7. https://doi.org/10.7314/APJCP.2013.14.2.631
  6. Hagedorn EJ, Sherwood DR (2011). Cell invasion through basement membrane: the anchor cell breaches the barrier. Curr Opin Cell Biol, 23, 589-96. https://doi.org/10.1016/j.ceb.2011.05.002
  7. Hu L, Wu QQ, Wang WB, et al (2013). Suppression of Ku80 correlates with radiosensitivity and telomere shortening in the U2OS telomerase-negative osteosarcoma cell line. Asian Pac J Cancer Prev, 14, 795-9. https://doi.org/10.7314/APJCP.2013.14.2.795
  8. Hwang JT, Park OJ, Lee YK, et al (2011). Anti-tumor effect of luteolin is accompanied by AMP-activated protein kinase and nuclear factor-kappaB modulation in HepG2 hepatocarcinoma cells. Int J Mol Med, 28, 25-31.
  9. Isomoto H (2009). Epigenetic alterations in cholangiocarcinomasustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing. Digestion, 79, 2-8. https://doi.org/10.1159/000167859
  10. Lavecchia A, Di Giovanni C, Novellino E (2012). CDC25 phosphatase inhibitors: an update. Mini Rev Med Chem, 12, 62-73. https://doi.org/10.2174/138955712798868940
  11. Lee EJ, Oh SY, Sung MK (2012). Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells. Food Chem Toxicol, 50, 4136-43. https://doi.org/10.1016/j.fct.2012.08.025
  12. Lim S, Kaldis P (2013). Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development, 140, 3079-93. https://doi.org/10.1242/dev.091744
  13. Lopez-Lazaro M (2009). Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem, 9, 31-59. https://doi.org/10.2174/138955709787001712
  14. Mihalache F, Tantau M, Diaconu B, Acalovschi M (2010). Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. J Gastrointestin Liver Dis, 19, 285-90.
  15. Pandurangan AK, Dharmalingam P, Sadagopan SK, et al (2013). Luteolin induces growth arrest in colon cancer cells through involvement of Wnt/beta-Catenin/GSK-3beta signaling. J Environ Pathol Toxicol Oncol, 32, 131-9. https://doi.org/10.1615/JEnvironPatholToxicolOncol.2013007522
  16. Patel V, Senderowicz AM, Pinto D, et al (1998). Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest, 102, 1674-81. https://doi.org/10.1172/JCI3661
  17. Prakobwong S, Khoontawad J, Yongvanit P, et al (2011). Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. Int J Cancer, 129, 88-100. https://doi.org/10.1002/ijc.25656
  18. Pratheeshkumar P, Son YO, Budhraja A, et al (2012). Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS One, 7, 52279. https://doi.org/10.1371/journal.pone.0052279
  19. Prawan A, Buranrat B, Kukongviriyapan U, Sripa B, Kukongviriyapan V (2009). Inflammatory cytokines suppress NAD(P)H:quinone oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells. J Cancer Res Clin Oncol, 135, 515-22. https://doi.org/10.1007/s00432-008-0483-2
  20. Ruan JS, Liu YP, Zhang L, et al (2012). Luteolin reduces the invasive potential of malignant melanoma cells by targeting beta3 integrin and the epithelial-mesenchymal transition. Acta Pharmacol Sin, 33, 1325-31. https://doi.org/10.1038/aps.2012.93
  21. Sankari SL, Masthan KM, Babu NA, Bhattacharjee T, Elumalai M (2012). Apoptosis in cancer--an update. Asian Pac J Cancer Prev, 13, 4873-8. https://doi.org/10.7314/APJCP.2012.13.10.4873
  22. Selvendiran K, Koga H, Ueno T, et al (2006). Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res, 66, 4826-34. https://doi.org/10.1158/0008-5472.CAN-05-4062
  23. Senggunprai L, Kukongviriyapan V, Prawan A, Kukongviriyapan U (2013). Quercetin and EGCG exhibit chemopreventive effects in cholangiocarcinoma cells via Suppression of JAK/STAT Signaling Pathway. Phytother Res, 28, 841-8.
  24. Sripa B, Brindley PJ, Mulvenna J, et al (2012). The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer. Trends Parasitol, 28, 395-407. https://doi.org/10.1016/j.pt.2012.07.006
  25. Suphim B, Prawan A, Kukongviriyapan U, et al (2010). Redox modulation and human bile duct cancer inhibition by curcumin. Food Chem Toxicol, 48, 2265-72. https://doi.org/10.1016/j.fct.2010.05.059
  26. Wang TT, Wang SK, Huang GL, Sun GJ (2012). Luteolin induced-growth inhibition and apoptosis of human esophageal squamous carcinoma cell line Eca109 cells in vitro. Asian Pac J Cancer Prev, 13, 5455-61. https://doi.org/10.7314/APJCP.2012.13.11.5455
  27. Zhao X, Sun X, Li XL (2012). Expression and clinical significance of STAT3, P-STAT3, and VEGF-C in small cell lung cancer. Asian Pac J Cancer Prev, 13, 2873-7. https://doi.org/10.7314/APJCP.2012.13.6.2873

Cited by

  1. Rutin mediated targeting of signaling machinery in cancer cells vol.14, pp.1, 2014, https://doi.org/10.1186/s12935-014-0124-6
  2. Chemical Library Screening and Structure-Function Relationship Studies Identify Bisacodyl as a Potent and Selective Cytotoxic Agent Towards Quiescent Human Glioblastoma Tumor Stem-Like Cells vol.10, pp.8, 2015, https://doi.org/10.1371/journal.pone.0134793
  3. Current Insights on Cholangiocarcinoma Research: a Brief Review vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1307
  4. Inflammation and Cancer Development in Pancreatic and Biliary Tract Cancer vol.66, pp.6, 2015, https://doi.org/10.4166/kjg.2015.66.6.325
  5. Hedyotis�diffusa Willd. extract suppresses proliferation and induces apoptosis via IL-6-inducible STAT3 pathway inactivation in human colorectal cancer cells pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.2956
  6. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents vol.37, pp.8, 2016, https://doi.org/10.1007/s13277-016-5015-0
  7. STAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma vol.43, pp.3, 2016, https://doi.org/10.1002/biof.1345
  8. and TPGS vol.68, pp.10, 2016, https://doi.org/10.1111/jphp.12598
  9. Inhibition of prostate cancer RM1 cell growth in vitro by hydroxyapatite nanoparticle-delivered short hairpin RNAs against Stat3 vol.16, pp.1, 2017, https://doi.org/10.3892/mmr.2017.6583
  10. Luteolin suppresses the JAK/STAT pathway in a cellular model of intestinal inflammation vol.8, pp.1, 2017, https://doi.org/10.1039/C6FO01529H
  11. Downregulation of NAD(P)H:quinone oxidoreductase 1 inhibits proliferation, cell cycle and migration of cholangiocarcinoma cells vol.13, pp.6, 2017, https://doi.org/10.3892/ol.2017.5951
  12. Luteolin-Mediated Inhibition of Hepatic Stellate Cell Activation via Suppression of the STAT3 Pathway vol.19, pp.6, 2018, https://doi.org/10.3390/ijms19061567